Recently, immunotherapeutic modalities with engineered cells and monoclonal antibodies have been effective in treating several malignancies. However, growing evidence suggests that immune-related adverse events (irAE) lead to severe and long-term side effects. Most iRAEs involve prolonged circulation of antibodies. To address this problem, nucleic acid aptamers can serve as alternative molecules to design immunotherapeutics with high functional diversity and predictable circulation times. Here, we report the first synthetic prototype consisting of DNA aptamers, which can activate T-cell receptor cluster of differentiation 3 (TCR-CD3) complex in cultured T-cells. We show that activation potential is similar to that of a monoclonal antibody (mAb) against TCR-CD3, suggesting the potential of aptamers in developing efficacious synthetic immunomodulators. The synthetic prototype of anti-TCR-CD3ε, as described herein, was designed using aptamer ZUCH-1 against TCR-CD3ε, generated by Ligand Guided Selection (LIGS). Aptamer ZUCH-1 was truncated and modified with nuclease-resistant RNA analogs to enhance stability. Several dimeric analogs with truncated and modified variants were designed with variable linker lengths to investigate the activation potential of each construct. Among them, dimeric aptamer with approximate dimensions similar to those of an antibody showed the highest T-cell-activation, suggesting the importance of optimizing linker lengths in engineering functional aptamers. The observed activation potential of dimeric aptamers shows the vast potential of aptamers in designing synthetically versatile immunomodulators with tunable pharmacokinetic properties, expanding immunotherapeutic designs with the use of nucleic acidbased ligands such as aptamers.
Evaluating the decrease in activation of TCR-CD3 in Jurkat E6.1 cells in the presence of the dimers (6S, 8S) and the absence of anti-CD28 antibodyCells were prepared by washing three times with 3 mL RPMI-1640 medium. 2 × 10 5 Jurkat E6.1 cells were incubated with OSJ-D-6S or OSJ-D-8S dimer in 150 µL cell suspension buffer in the absence of anti-CD28 antibody at 37°C with 5% CO 2 in a surface-modified polystyrene 96 well flat bottom plate. Cells were stained with 5 µL of 100 µg/mL CD69 mouse anti-human Cy5.5 antibody for 45 mins on ice then washed one time with 2 mL RPMI-1640 and reconstituted in 250 µL RPMI-1640 medium. The expression of activation marker CD69 was monitored in FL4 at each time points using flow cytometry by counting 5000 events.
Evaluating the lack of activation of TCR-CD3 in Jurkat E6.1 cells using the random dimerCells were prepared by washing three times with 3 mL RPMI-1640 medium. 2 × 10 5 Jurkat E6.1 cells were incubated for 2, 4 and 6 hours with 0.15 nmole random dimer in 150 µL cell suspension buffer in the presence of 10 µL of 25 µg/mL unlabeled anti-CD28 at 37°C with 5% CO 2 in a surface-modified polystyrene 96 well flat bottom plate. Following incubation, cells were stained with 5 µL of 100 µg/mL CD69 mouse anti-human Cy5.5 antibody for...